Specificity and mechanism of tRNA cleavage by the AriB Toprim nuclease of the PARIS bacterial immune system.

Fiche publication

Date publication

septembre 2025

Journal

Philosophical transactions of the Royal Society of London. Series B, Biological sciences

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MOTORINE Iouri , Dr MARCHAND Virginie

Tous les auteurs :
Belukhina S, Saudemont B, Depardieu F, Lorthios T, P Maviza T, Livenskyi A, Serebryakova M, Aleksandrova M, Ukholkina E, Burmistrova N, Sergiev P, Libiad M, Dubrac S, Barras F, Motorin Y, Marchand V, Hagelueken G, Isaev A, Bikard D, Rouillon C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40904115

Résumé

Transfer RNA (tRNA) molecules have been recently recognized as widespread targets of bacterial immune systems. Translation inhibition through tRNA cleavage or modification inhibits phage propagation, thereby protecting the bacterial population. To counteract this, some viruses encode their own tRNA molecules, allowing infection to take place. The AriB effector of the PARIS defence system is a Toprim nuclease previously shown to target the tRNA, but not a tRNA variant encoded by bacteriophage T5. We demonstrate here that the T5 tRNA is required but not sufficient to bypass PARIS immunity. Combining tRNA sequencing, genetics, phage infection and biochemical data, we reveal that the tRNA is another prime target of AriB, and tRNA represents a secondary, yet biologically relevant, target of the PARIS effector. Activated AriB protein cleaves these targets , and the cleavage reaction is not dependent on the presence of specific tRNA modifications. We show that the overexpression of phage T5 tRNA, tRNA and tRNA variants is sufficient to inhibit PARIS anti-viral defence. Finally, we propose a model for tRNA recognition by the AriB dimer and provide molecular details of its nuclease activity and specificity.This article is part of the discussion meeting issue 'The ecology and evolution of bacterial immune systems'.